Clinical Trial Update: 3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer [Phase 3]

View source ↗

Summary

This update reports on a Phase 3 trial comparing three years of anastrozole versus no treatment as extended adjuvant therapy for postmenopausal women with breas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Neoplasms | Phase 3 | Status: COMPLETED